.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,017,615

« Back to Dashboard

Claims for Patent: 8,017,615

Title:Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Inventor(s): Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Naruto, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Naruto, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Naruto, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Naruto, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Tokushima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:11/790,605
Patent Claims: 1. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating Anhydrous Aripiprazole Crystals B with one or more pharmaceutically acceptable carriers, obtaining granules of Anhydrous Aripiprazole Crystals B, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain a pharmaceutical solid oral preparation wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.40% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less.

2. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating Anhydrous Aripiprazole Crystals B with one or more pharmaceutically acceptable carriers, obtaining granules of Anhydrous Aripiprazole Crystals B, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain a pharmaceutical solid oral preparation wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.10% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less.

3. A pharmaceutical solid oral preparation comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity and one or more pharmaceutically acceptable carriers, wherein said low hygroscopicity is a moisture content of 0.40% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; wherein said Crystals have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

4. A pharmaceutical solid oral preparation comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity and one or more pharmaceutically acceptable carriers, wherein said low hygroscopicity is a moisture content of 0.10% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; wherein said Crystals have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

5. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating conventional Anhydrous Aripiprazole Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Anhydrous Aripiprazole Crystals, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain a pharmaceutical solid oral preparation.

6. A pharmaceutical solid oral preparation prepared by wet granulating conventional Anhydrous Aripiprazole Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Anhydrous Aripiprazole Crystals, drying the obtained granules at 70 to 100.degree. C., sizing the obtained granules, and then drying the sized granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain said pharmaceutical solid oral preparation wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

7. The pharmaceutical solid oral preparation prepared by the process of claim 5, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

8. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating conventional Aripiprazole Hydrate Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Aripiprazole Hydrate Crystals, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain the pharmaceutical solid oral preparation.

9. A pharmaceutical solid oral preparation prepared by wet granulating conventional Aripiprazole Hydrate Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Aripiprazole Hydrate Crystals, drying the obtained granules at 70 to 100.degree. C., sizing the obtained granules, and then drying the sized granules at 70 to 100.degree. C. for 1 to 6 hours again, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

10. The pharmaceutical solid oral preparation prepared by the process of claim 8, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

11. A process for preparing a pharmaceutical solid oral preparation of Anhydrous Aripiprazole Crystals B and one or more pharmaceutically acceptable carriers comprising heating Aripiprazole Hydrate A at 90 to 125.degree. C. for about 3 to 50 hours wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.40% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less; and said Aripiprazole Hydrate A has a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 15.4.degree., 17.3.degree., 18.0.degree., 18.6.degree., 22.5.degree. and 24.8.degree.; particular infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963, and 784 cm.sup.-1 on the IR (KBr) spectrum; a thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min) endothermic curve characterized by the appearance of a peak at about 71.degree. C. and an endothermic peak around 60.degree. C. to 120.degree. C.; and a mean particle size of 50 .mu.m or less.

12. A process for preparing a pharmaceutical solid oral preparation of Anhydrous Aripiprazole Crystals B and one or more pharmaceutically acceptable carriers comprising heating Aripiprazole Hydrate A at 90 to 125.degree. C. for about 3 to 50 hours wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.10% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less; and wherein said Aripiprazole Hydrate A has a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 15.4.degree., 17.3.degree., 18.0.degree., 18.6.degree., 22.5.degree. and 24.8.degree.; particular infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963, and 784 cm.sup.-1 on the IR (KBr) spectrum; a thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min) endothermic curve characterized by the appearance of a peak at about 71.degree. C. and an endothermic peak around 60.degree. C. to 120.degree. C.; and a mean particle size of 50 .mu.m or less.

13. The process according to claim 1, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

14. The process according to claim 2, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

15. The pharmaceutical solid oral preparation according to claim 3, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

16. The pharmaceutical solid oral preparation according to claim 4, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

17. The process according to claim 11, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

18. The process according to claim 12, wherein the mean particle size is measured using a laser diffraction particle size analyzer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc